{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:16:46Z","timestamp":1761513406752,"version":"3.40.4"},"reference-count":39,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":584,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1002\/jcph.269","type":"journal-article","created":{"date-parts":[[2014,1,20]],"date-time":"2014-01-20T05:56:44Z","timestamp":1390197404000},"page":"361-367","source":"Crossref","is-referenced-by-count":12,"title":["Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: A reason for the variable efficacy of albendazole and praziquantel?"],"prefix":"10.1002","volume":"54","author":[{"given":"Matthew L.","family":"Romo","sequence":"first","affiliation":[{"name":"CUNY School of Public Health; New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arturo","family":"Carpio","sequence":"additional","affiliation":[{"name":"School of Medicine; University of Cuenca; Cuenca Ecuador"},{"name":"GH Sergievsky Center, College of Physicians and Surgeons; Columbia University; New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Kelvin","sequence":"additional","affiliation":[{"name":"CUNY School of Public Health; New York NY USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,1,25]]},"reference":[{"key":"10.1002\/jcph.269-BIB0001|jcph269-cit-0001","doi-asserted-by":"crossref","first-page":"e1500","DOI":"10.1371\/journal.pntd.0001500","article-title":"Neurocysticercosis: neglected but not forgotten","volume":"6","author":"Coyle","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1002\/jcph.269-BIB0002|jcph269-cit-0002","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1179\/2047773212Y.0000000028","article-title":"Neurocysticercosis in the United States","volume":"106","author":"Serpa","year":"2012","journal-title":"Pathog Glob Health"},{"key":"10.1002\/jcph.269-BIB0003|jcph269-cit-0003","doi-asserted-by":"crossref","first-page":"e69537","DOI":"10.1371\/journal.pone.0069537","article-title":"Epidemiology and management of cysticercosis and taenia solium taeniasis in Europe, systematic review 1990-2011","volume":"8","author":"Zammarchi","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1002\/jcph.269-BIB0004|jcph269-cit-0004","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1212\/WNL.0b013e31828c2f3e","article-title":"Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"80","author":"Baird","year":"2013","journal-title":"Neurology"},{"key":"10.1002\/jcph.269-BIB0005|jcph269-cit-0005","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1473-3099(02)00454-1","article-title":"Neurocysticercosis: an update","volume":"2","author":"Carpio","year":"2002","journal-title":"Lancet Infect Dis"},{"key":"10.1002\/jcph.269-BIB0006|jcph269-cit-0006","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1212\/CPJ.0b013e31828d9f17","article-title":"Neurocysticercosis: five new things","volume":"3","author":"Carpio","year":"2013","journal-title":"Neurol Clin Pract"},{"key":"10.1002\/jcph.269-BIB0007|jcph269-cit-0007","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/jnnp.2008.144899","article-title":"Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial","volume":"79","author":"Carpio","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/jcph.269-BIB0008|jcph269-cit-0008","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa031294","article-title":"A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis","volume":"350","author":"Garcia","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/jcph.269-BIB0009|jcph269-cit-0009","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/BF00608219","article-title":"Pharmacokinetics of albendazole in man","volume":"30","author":"Marriner","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jcph.269-BIB0010|jcph269-cit-0010","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2125.2000.00170.x","article-title":"Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes","volume":"49","author":"Rawden","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1002\/jcph.269-BIB0011|jcph269-cit-0011","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1128\/AAC.01465-12","article-title":"In vitro analysis of albendazole sulfoxide enantiomers shows that (+)-(R)-albendazole sulfoxide is the active enantiomer against Taenia solium","volume":"57","author":"Paredes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jcph.269-BIB0012|jcph269-cit-0012","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00228-003-0636-9","article-title":"Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data","volume":"59","author":"Li","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jcph.269-BIB0013|jcph269-cit-0013","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/ecp.11.72","article-title":"Pharmacokinetic variability of anthelmintics: implications for the treatment of neurocysticercosis","volume":"5","author":"Jung-Cook","year":"2012","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1002\/jcph.269-BIB0014|jcph269-cit-0014","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0022-3565(25)22160-7","article-title":"Albendazole sulfonation by rat liver cytochrome P-450c","volume":"246","author":"Souhaili-El Amri","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1002\/jcph.269-BIB0015|jcph269-cit-0015","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1590\/S0100-879X2002000200016","article-title":"Albendazole metabolism in patients with neurocysticercosis: antipyrine as a multifunctional marker drug of cytochrome P450","volume":"35","author":"Marques","year":"2002","journal-title":"Braz J Med Biol Res."},{"key":"10.1002\/jcph.269-BIB0016|jcph269-cit-0016","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00228-009-0683-y","article-title":"Effect of ritonavir on the pharmacokinetics of the benzimidazoles albendazole and mebendazole: an interaction study in healthy volunteers","volume":"65","author":"Corti","year":"2009","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1002\/jcph.269-BIB0017|jcph269-cit-0017","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00007691-200206000-00003","article-title":"Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis","volume":"24","author":"Lanchote","year":"2002","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.269-BIB0018|jcph269-cit-0018","first-page":"679","article-title":"Population pharmacokinetics of albendazole in patients with neurocysticercosis","volume":"47","author":"Castro","year":"2009","journal-title":"Int J Clin Pharmacol Ther."},{"key":"10.1002\/jcph.269-BIB0019|jcph269-cit-0019","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF00560463","article-title":"Clinical pharmacology in normal volunteers of praziquantel, a new drug against schistosomes and cestodes. An example of a complex study covering both tolerance and pharmacokinetics","volume":"14","author":"Leopold","year":"1978","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1002\/jcph.269-BIB0020|jcph269-cit-0020","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1365-2125.2010.03874.x","article-title":"Albendazole-praziquantel interaction in healthy volunteers: kinetic disposition, metabolism and enantioselectivity","volume":"71","author":"Lima","year":"2011","journal-title":"Br J Clin Pharmacol."},{"key":"10.1002\/jcph.269-BIB0021|jcph269-cit-0021","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2710.2007.00862.x","article-title":"Pharmacokinetic interaction between ketoconazole and praziquantel in healthy volunteers","volume":"32","author":"Ridtitid","year":"2007","journal-title":"J Clin Pharm Ther."},{"key":"10.1002\/jcph.269-BIB0022|jcph269-cit-0022","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1067\/mcp.2002.129319","article-title":"Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers","volume":"72","author":"Ridtitid","year":"2002","journal-title":"Clin Pharmacol Ther."},{"key":"10.1002\/jcph.269-BIB0023|jcph269-cit-0023","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","article-title":"Enzyme induction with antiepileptic drugs: cause for concern?","volume":"54","author":"Brodie","year":"2013","journal-title":"Epilepsia"},{"key":"10.1002\/jcph.269-BIB0024|jcph269-cit-0024","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia"},{"key":"10.1002\/jcph.269-BIB0025|jcph269-cit-0025","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF00314741","article-title":"Dexamethasone increases plasma levels of albendazole","volume":"237","author":"Jung","year":"1990","journal-title":"J. Neurol"},{"key":"10.1002\/jcph.269-BIB0026|jcph269-cit-0026","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00007691-199702000-00009","article-title":"Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone","volume":"19","author":"Takayanagui","year":"1997","journal-title":"Ther. Drug Monit"},{"key":"10.1002\/jcph.269-BIB0027|jcph269-cit-0027","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1212\/WNL.42.3.492","article-title":"Phenytoin and carbamazepine decreased oral bioavailability of praziquantel","volume":"42","author":"Bittencourt","year":"1992","journal-title":"Neurology"},{"key":"10.1002\/jcph.269-BIB0028|jcph269-cit-0028","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/infdis\/169.3.689","article-title":"Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants","volume":"169","author":"Dachman","year":"1994","journal-title":"J. Infect. Dis"},{"key":"10.1002\/jcph.269-BIB0029|jcph269-cit-0029","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1002\/jcph.269-BIB0030|jcph269-cit-0030","unstructured":"Cuadro Nacional de Medicamentos B\u00e1sicos-Ecuador. Available at Accessed January 15, 2009 2014 http:\/\/www.who.int\/selection_medicines\/country_lists\/ecu_cuadro_general.pdf"},{"key":"10.1002\/jcph.269-BIB0031|jcph269-cit-0031","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1002\/jcph.269-BIB0032|jcph269-cit-0032","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1212\/WNL.37.9.1561","article-title":"Plasma levels of praziquantel decrease when dexamethasone is given simultaneously","volume":"37","author":"Vazquez","year":"1987","journal-title":"Neurology"},{"key":"10.1002\/jcph.269-BIB0033|jcph269-cit-0033","doi-asserted-by":"crossref","first-page":"260","DOI":"10.4269\/ajtmh.2002.66.260","article-title":"Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability","volume":"66","author":"Nagy","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"10.1002\/jcph.269-BIB0034|jcph269-cit-0034","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/dmd.30.4.365","article-title":"The anthelminthic agent albendazole does not interact with p-glycoprotein","volume":"30","author":"Merino","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jcph.269-BIB0035|jcph269-cit-0035","first-page":"33","article-title":"The influence of cimetidine on plasma levels of praziquantel after a single day therapeutic regimen","volume":"40","author":"Castro","year":"1997","journal-title":"Proc West Pharmacol Soc"},{"key":"10.1002\/jcph.269-BIB0036|jcph269-cit-0036","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1742-7843.2005.pto_172.x","article-title":"Influence of a Mexican diet on the bioavailability of albendazole","volume":"97","author":"Mares","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1002\/jcph.269-BIB0037|jcph269-cit-0037","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1128\/AAC.44.10.2903-2904.2000","article-title":"Bioavailability of praziquantel increases with concomitant administration of food","volume":"44","author":"Castro","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jcph.269-BIB0038|jcph269-cit-0038","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1212\/WNL.52.5.1079","article-title":"Single-day praziquantel versus 1-week albendazole for neurocysticercosis","volume":"52","author":"Del Brutto","year":"1999","journal-title":"Neurology"},{"key":"10.1002\/jcph.269-BIB0039|jcph269-cit-0039","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00002826-199012000-00008","article-title":"Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis","volume":"13","author":"Jung","year":"1990","journal-title":"Clin Neuropharmacol"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.269","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcph.269\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T16:10:06Z","timestamp":1746115806000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,25]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.269","relation":{},"ISSN":["0091-2700"],"issn-type":[{"type":"print","value":"0091-2700"}],"subject":[],"published":{"date-parts":[[2014,1,25]]}}}